Drug Prices
Hospitals appreciate the support and resources that Congress have provided throughout the COVID-19 pandemic; however, additional support is needed to keep hospitals strong so they can continue to provide care to patients and communities.
- Finance & Budgeting
- Cost Management
- Novel Coronavirus (SARS-CoV-2/COVID-19)
- COVID-19: Coverage and Reimbursement
- Workforce
- Nurses
- COVID-19: Supplies and Personal Protective Equipment (PPE)
- Drug Prices
- Workforce Supply and Demand
- Novel Coronavirus (SARS-CoV-2/COVID-19)
- Advocacy & Public Policy
- Telling the Hospital Story
Hospitals appreciate the support and resources that Congress have provided throughout the COVID-19 pandemic; however, additional support is needed to keep hospitals strong so they can continue to provide care to patients and communities.
It’s no secret that billionaire Mark Cuban has his mind and assets focused on disrupting drug pricing in the U.S. But during a recent talk, Cuban shared new information about what his Cost Plus Drugs company is doing with payers and pharmacists.
The Medicare Payment Advisory Commission today voted to recommend Congress adopt additional site-neutral payment policies for certain outpatient services; reduce add-on payments and adopt other policies to address high Medicare Part B drug costs; and repeal the existing Medicare wage index system…
The state of California put up $50 million to have Civica Rx manufacture and distribute low-cost biosimilars for the three most used short- and long-acting insulins.
The Centers for Medicare & Medicaid Services this week released for comment initial guidance implementing a program for Medicare to negotiate prices with drug makers for certain high-cost, single-source drug and biological products beginning in 2026 under the Inflation Reduction Act.
The Centers for Medicare and Medicaid Services (CMS) March 15 announced 27 prescription drugs for which it will lower Part B beneficiary coinsurance, beginning April 1 through June 30, 2023, as required by the Inflation Reduction Act (IRA).
The Centers for Medicare and Medicaid Services (CMS) March 15 announced 27 prescription drugs for which it will lower Part B beneficiary coinsurance, beginning April 1 through June 30, 2023, as required by the Inflation Reduction Act (IRA). This is a table of those drugs.
This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere between 10% and 19.9%, depending on the drug, the Centers for Medicare & Medicaid Services announced today.
The market for biosimilar drugs to treat cancer, inflammatory diseases, diabetes and more will continue to expand, ideally resulting in lower prices as more pharmaceutical patents expire and competitors enter the market.